Theralase Technologies Inc. V.TLT

Just three more weeks

[gojotv!]

'Til we get 120-day results for the first three patients having received the full two treatments in the Phase 2 NMIBC study.
This is the big one, folks!
After the 2020 we've had, good boys and girls like us deserve a very Merry Christmas!
GLTA real TLT investors!

[tamarindo1]

Expect to see the share price creep up in anticipation. Great Expectations:  C. J. D.   :-)

[ScienceFirst]

120 days is not even a milestone in the clinical trial! Don't know what you guys are talking about!

[Longholder99]

Nobody here.....not even newly minted yesterday naysayers....can say with much more reliability beyond a guess, what this company will or will not release and when. Opionions are like a**holes....everyone has one. This is why you do your own DD and stick with long standing intelligent posters who actually contribute decent info when you are looking for perspective. Just saying....

[CancerSlayer]

  Ever heard of a 90 day CR?  It may just happen to be a good indication of an effective or promising cancer treatment.  120 day data even better.  Can you name another PDT option for this indication currently in trial that shows any promise?  Can you name "any" investigational drug in trial that is a stand-alone treatment &/or only requires TWO treatments.

[ScienceFirst]

It has nothing to do with how promising or not is a drug/treatment. It simply has to do with clear endpoints specified in a clinical trial.  That's how work all trials.  And in this case, 90 days (CR) and 365 days (durable response) are the specific endpoints and this is the same for all NMIBC non-responsive trials as this is what is recommended by the FDA (go see the 2018 FDA

[CancerSlayer]

Think we're in agreement.  A DOR for any trial is the key endpoint.  Though a 90 day CR is less significant, from an early investor or risk-taking perspective, it can provide an early window into a given treatment's "durable" efficacy, especially in view of prior promising test results (Ph 1 secondary endpoint/efficacy).  

[CancerSlayer]

Sorry, DOR is duration of response.

[Longholder99]

The minutes you spend in your life dealing with bashers.....you dont get those back. I use the Ignore function.

[ScienceFirst]

In my previous post, I forgot to mention "@120 days", as this was the whole point of the initial discussion.  So it should have read like this: The design of the clinical trial doesn't even include a meeting between the urologist and the patient @120 days.  ######################################################################### It has nothing to do with how

[enriquesuave]

"During the Follow-Up Phase, information on efficacy and safety will be collected. Assessments will be conducted at Day 0, 7, 30, 60, 90, 180, 187, 210, 240, 270 and 360." 90 days CR for 2 Nd batch of patients and 9 months data on first set will be interesting.  Hopefully they will give us data and it will be good given optimized treatment.  We will be able to evaluate how

[CancerSlayer]

  Radachlorin...That's a blast from the past (2013 NMIBC study).  What ever happened to it?  Seemed to have a lot of promise, but never got approved for NMIBC.  I noted in that study that of all 34 patients treated, the mean number of prior BCG instillations was only 1.68, indicating most patients were likely BCG "intolerant" & hence wouldn't have met

[enriquesuave]

In the case of TLD-1433 PDT, I personally don't think that BCG responsiveness will make a difference.  In other words it should be as effective in either case  IMO.  BCG stimulates a nonspecific immune response versus TLD-1433 PDT which selectively destroys 98-100% of all cancer cells activated by green light, leaving healthy urothelium intact, and then creates a more specific

[CancerSlayer]

Agree.  I was just comparing the potential of TLD 1433 with that of Radachlorin, irrespective of BCG responsiveness.  Considering Radachlorin's excellent 12 month CR rate in that 2013 study, I was surprised it didn't move forward?  Seemed to be a perfect candidate at the time.  Regardless, TLT currently appears to be the only "promising" holder of the PDT

[enriquesuave]

I'm not too sure why Radachlorin is not widely used for bladder cancer, perhaps they knew an instilled better drug was coming vs IV and also their Dosimetry was maybe not up to par and the use of red light may be less desirable given the potential for damaging muscle layer.  IMO. This procedure needs to be easily reproducible and Theralase has simplified it tremendously with TLD-1433 and

[Yajne]

Thanks for reminding us of the follow-up data collection points. It seems to me that the PI may be asked to reveal the data more frequently in light of TLD1433's FTD designation...to support the ongoing dialog with the FDA, one of the benefits of FTD status. That should provide TLT an opportunity to support the sp, if data continues to be positive. I guess we will soon see if PI is more

[gojotv!]

Sorry, folks, that's a typo... I meant to say 180 days. Of course, those who've been following this story knew what I meant, because it was 90 days in September... So, those who are trying to,baffle readers by pretending they don't know what was meant... well... GLTA real investors and TLT cancer-killing enthusiasts!